Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/14219
Full metadata record
DC FieldValueLanguage
dc.contributor.authorInstituto Nacional de Câncer José Alencar Gomes da Silva-
dc.contributor.authorInstituto Nacional de Câncer (Brasil)-
dc.contributor.authorINCA-
dc.date.accessioned2023-06-19T19:09:40Z-
dc.date.available2023-06-19T19:09:40Z-
dc.date.issued2005-12-
dc.identifier.urihttps://ninho.inca.gov.br/jspui/handle/123456789/14219-
dc.publisherINCApt_BR
dc.subjectFarmacovigilânciapt_BR
dc.subjectPharmacovigilancept_BR
dc.subjectFarmacovigilanciapt_BR
dc.subjectEfeitos Colaterais e Reações Adversas Relacionados a Medicamentospt_BR
dc.subjectDrug-Related Side Effects and Adverse Reactionspt_BR
dc.subjectEfectos Colaterales y Reacciones Adversas Relacionados con Medicamentospt_BR
dc.subjectUso de Medicamentospt_BR
dc.subjectDrug Utilizationpt_BR
dc.subjectUtilización de Medicamentospt_BR
dc.titleII Oficina de Farmacovigilância do INCApt_BR
dc.title.alternativeInforme INCA 208pt_BR
dc.TypePeriodicalpt_BR
Appears in Collections:Informe INCA 208

Files in This Item:
File Description SizeFormat 
Informe-INCA-2005-208-3-IIOficina-de-Farmacovigilância.pdf150.2 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.